Age, socioeconomic status, and co-existing conditions are among the factors that can lead to a need for assisted ventilation in people with amyotrophic lateral sclerosis (ALS), research from Korea reports. The study, “Factors associated with assisted ventilation use in amyotrophic lateral sclerosis: a nationwide population-based study in Korea,”…

Certain blood biomarkers of lipid, or fat, metabolism — typically measured to determine a person’s risk of cardiovascular disease — appear to protect against developing amyotrophic lateral sclerosis (ALS), a study of more than 500,000 adults reported. Specifically, researchers found that people with higher levels of high density lipoprotein (HDL)…

Total job- and leisure-related physical activity over a lifetime is not a risk factor for amyotrophic lateral sclerosis (ALS), but heavy physical activity on the job is associated with a nearly two-times greater risk of ALS, a study in Germany shows. Also, ALS patients reporting pre-diagnosis and current moderate…

Using a new laboratory model of brain cells, researchers demonstrated that cells with mutations associated with amyotrophic lateral sclerosis (ALS) show early signs of DNA damage and other forms of cellular stress. Results suggest that blocking these cellular stress processes may hold promise in treating ALS. The study, “…

A Phase 2 study of the investigational antibody AT-1501 in treating amyotrophic lateral sclerosis (ALS) has completed patient enrollment in three of its four dosing groups, and is likely to be fully enrolled by year’s end, its developer, Eledon Pharmaceuticals, announced. A total of 54 ALS patients diagnosed in the…

New early clinical study results support the potential of GN-K01, an investigational antibody being developed by GeNeuro, as a treatment for amyotrophic lateral sclerosis (ALS). The therapy may enter clinical trials as early as 2022, according to the company. The antibody targets a viral protein, called HERV-K ENV,…

A detailed atlas of the various types of cells that populate the motor cortex, the brain region that controls voluntary movement and is damaged in people with amyotrophic lateral sclerosis (ALS), was created by a worldwide consortium of researchers. The long-term goal of the group, which involves hundreds of…

Tofersen, an experimental treatment for amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, failed to significantly slow the rate of disease progression relative to a placebo in a Phase 3 trial. These top-line findings mean that the VALOR study (NCT02623699), which is testing tofersen in…

The ALS Association is reminding amyotrophic lateral sclerosis (ALS) patients and caregivers that the open enrollment period for Medicare recipients to make changes to their existing coverage runs through Dec. 7. The open enrollment period for altering coverage opened Friday. After Dec. 7. changes will be allowed only after…

Note: This story was updated Oct. 19, 2021, to note that the trial is taking place at 90 clinical sites and to update the contact information, based on additional information from the company. A Phase 3b clinical trial is recruiting adults with amyotrophic lateral sclerosis (ALS) to assess the…